Skip to main content

Animations

Funded Studies

The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.

Search or browse funded studies

Previously funded studies appear chronologically, with the most recent appearing first.

Filters
From
To
  • ${value}

Filter Results (2353${count})

  • Fall 2021 RFP: Accelerating Early Proof-of-Concept Testing of Promising PD Therapies, 2022
    Targeting the Interaction of Alpha-synuclein with Lipids as a Therapeutic for Parkinson’s Disease

    Study Rationale: Parkinson’s disease (PD) is characterized by an abnormal accumulation of alpha-synuclein. One of this protein’s normal functions involves binding to fatty acids and lipids, and...

  • Fall 2021 RFP: Expanding Biological Understanding of PD, 2022
    Evaluation of Gene Products that Counteract the Action of LRRK2

    Study Rationale: Although most cases of Parkinson’s disease (PD) are of unknown origin, some forms can be inherited. Mutations that activate the enzyme LRRK2 are a major cause of inherited PD, and...

  • Alpha-synuclein Seed Amplification Assay Program, 2021
    Detection of Single Molecules of Alpha-synuclein in Extracellular Vesicles

    Study Rationale: The pathological changes observed in the brain tissue of people with Parkinson’s disease (PD) compared to healthy individuals motivated researchers to explore alpha-synuclein as a...

  • Fall 2021 RFP: Accelerating Early Proof-of-Concept Testing of Promising PD Therapies, 2021
    Evaluation of “PDRepair,” a Novel Neuroprotective and Neurorestorative Therapeutic for GBA1-associated Parkinson’s Disease

    Study Rationale: Mutations in the GBA1 gene, which encodes an enzyme called GCase, is the strongest genetic risk factor for Parkinson’s Disease (PD) and most often results in the production of GCase...

  • Fall 2021 RFP: Accelerating Early Proof-of-Concept Testing of Promising PD Therapies, 2021
    Preclinical Efficacy and Biomarker Development for a Clinical Stage Inhibitor of Lipid Metabolism in Parkinson’s Disease

    Study Rationale: A hallmark characteristic of Parkinson’s disease (PD) is the accumulation of alpha-synuclein, a small lipid-binding protein involved in transporting lipids and proteins throughout the...

  • Fall 2021 RFP: Accelerating Early Proof-of-Concept Testing of Promising PD Therapies, 2021
    Establishing the Therapeutic Potential of Engineered Neural Circuits in a Preclinical Model of Parkinson’s Disease

    Study Rationale: Parkinson’s disease (PD) is caused by the death of specific brain cells that connect two different regions of the brain, disrupting a neural circuit that is key for motor function. We...

Two female doctors talking in the lab.

Apply for a Grant

Our funding programs support basic, translational and clinical research from academia and industry.

See Funding Opportunities
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.